IDH1 MUTATION
Clinical trials for IDH1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new IDH1 MUTATION trials appear
Sign up with your email to follow new studies for IDH1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising Triple-Drug combo targets tough leukemia mutation
Disease control Recruiting nowThis study is testing a three-drug combination (venetoclax, ivosidenib, and azacitidine) in adults with a specific genetic form of acute myeloid leukemia (AML) called IDH1-mutated. The goal is to see if this combination can improve remission rates and survival. About 23 participa…
Matched conditions: IDH1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 09:52 UTC
-
New hope for AML patients: targeted pill may keep cancer away after transplant
Disease control Recruiting nowThis study tests whether a daily pill called ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 75 adults with a specific IDH1 gene mutation will receive either the drug or a placebo. The goal is to see if the drug extend…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New triple-drug combo aims to improve leukemia treatment without standard chemo
Disease control Recruiting nowThis study tests a combination of three drugs (olutasidenib, venetoclax, and azacitidine) in people with a specific genetic form of acute myeloid leukemia (IDH1 mutation). The goal is to see if this combo is safer and works better than standard intensive chemotherapy. About 16 ad…
Matched conditions: IDH1 MUTATION
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated May 22, 2026 14:04 UTC